AstraZeneca and Bristol Myers Squibb are reportedly holding talks about a potential merger that could become one of the biggest deals in biopharma history, according to the Financial Times. A combination would bring together AstraZeneca’s oncology, cardiovascular and immunology footprint with BMS’s portfolio led by immunology and multiple oncology franchises. While details were not provided, the report underscores how scale and pipeline breadth continue to drive consolidation discussions among large pharma companies. For the companies, a deal of this size would likely reshape R&D priorities, geographic operations, and cost structures. Investors will focus on deal terms, potential antitrust pathways, and whether management changes would follow any transaction. The news also adds urgency to how each company positions late-stage assets and platform investments ahead of potential integration planning.